Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

35.38 -0.34 (-0.94%)

Delayed Quote Updated: 10:49 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

Via The Motley Fool

Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement

March 05, 2026

In a landmark resolution that removes a multi-year shadow over the messenger RNA (mRNA) industry, Moderna, Inc. (NASDAQ:MRNA) has reached a comprehensive $2.25 billion global settlement with Genevant...

Via MarketMinute

Topics Intellectual Property Lawsuit

BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide ↗

March 04, 2026

BlackBarn Capital has raised its investment in Warby Parker, a direct-to-consumer eyewear brand recognized for its affordable frames and expanding network of stores. As Warby Parker opens more...

Via The Motley Fool

Topics Regulatory Compliance

Why Did Roivant Sciences Stock Gain 9% Pre-Market Today? ↗

February 06, 2026

Via Stocktwits

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗

March 04, 2026

The news is likely to come as a relief to many investors, Citi told investors in a research note.

Via Stocktwits

Topics Intellectual Property

MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗

March 03, 2026

The settlement resolves all enforcement actions involving Moderna’s use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines.

Via Stocktwits

Topics Intellectual Property

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

March 03, 2026

From Arbutus Biopharma Corporation

Via GlobeNewswire

Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

March 03, 2026

From Roivant Sciences

Via GlobeNewswire

Earnings Preview For Roivant Sciences ↗

November 07, 2025

Via Benzinga

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

March 03, 2026

From Roivant Sciences

Via GlobeNewswire

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential ↗

February 13, 2026

This audio and imaging technology provider licenses Dolby Atmos and Vision to global entertainment and device markets.

Via The Motley Fool

Topics Regulatory Compliance

TTMI Stock Soars 250% in One Year, and One Fund Is Betting $7 Million on More Growth ↗

February 13, 2026

TTM Technologies supplies advanced printed circuit boards and RF components for high-reliability applications across diverse industries.

Via The Motley Fool

Topics Artificial Intelligence Supply Chain

Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out ↗

February 13, 2026

American Healthcare REIT manages a diverse portfolio of healthcare properties across the U.S. and U.K., serving institutional tenants.

Via The Motley Fool

Topics Regulatory Compliance

The market is filled with gapping stocks in Friday's session. ↗

February 06, 2026

Via Chartmill

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...

Via Finterra

Topics ETFs Economy Initial Public Offering

Get insights into the top gainers and losers of Friday's pre-market session. ↗

February 06, 2026

Via Chartmill

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

February 06, 2026

From Roivant Sciences

Via GlobeNewswire

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

February 06, 2026

From Pulmovant, Inc.

Via GlobeNewswire

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

February 06, 2026

From Roivant Sciences

Via GlobeNewswire

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

January 26, 2026

In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500....

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

January 23, 2026

From Roivant Sciences

Via GlobeNewswire

Roivant Signals Major Pipeline Momentum With Accelerated Timelines ↗

December 11, 2025

Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.

Via Benzinga

Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day

December 11, 2025

From Roivant Sciences

Via GlobeNewswire

Roivant (ROIV) Q2 2026 Earnings Call Transcript ↗

November 27, 2025

Roivant (ROIV) Q2 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

Looking Into Roivant Sciences Ltd's Recent Short Interest ↗

November 11, 2025

Via Benzinga

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

November 10, 2025

From Roivant Sciences

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.